Interleukin-13 receptor α2 is a novel marker and potential therapeutic target for human melanoma.
Saved in:
| Title: | Interleukin-13 receptor α2 is a novel marker and potential therapeutic target for human melanoma. |
|---|---|
| Authors: | Okamoto H; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Yoshimatsu Y; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.; Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Tomizawa T; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Kunita A; Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Takayama R; Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Morikawa T; Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Komura D; Department of Genomic Pathology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Takahashi K; Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Oshima T; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Sato M; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Komai M; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Podyma-Inoue KA; Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Uchida H; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.; Project Division of Cancer Biomolecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Hamada H; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan., Fujiu K; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Department of Advanced Cardiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Ishikawa S; Department of Genomic Pathology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Fukayama M; Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Fukuhara T; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.; Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan., Watabe T; Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. t-watabe@umin.ac.jp.; Department of Biochemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan. t-watabe@umin.ac.jp. |
| Source: | Scientific reports [Sci Rep] 2019 Feb 04; Vol. 9 (1), pp. 1281. Date of Electronic Publication: 2019 Feb 04. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2045-2322 |
|---|---|
| DOI: | 10.1038/s41598-019-39018-3 |
